CD86 and neoplasm: The mean histoscore for CD86 (M1 macrophage marker) was significantly higher in DLBCL samples than in non-tumor controls (5.4 ± 1.1 vs 3.4 ± 1.0, p = 9.0e-08) as well as the mean CD86+ cell percentage (74.6% ± 17.8 vs 27.9% ± 7.8, p = 4.0e-24) (Figure 4A).